Non-metabolic causes of steatotic liver disease

Abstract

Hepatic steatosis is caused by exaggerated hepatic lipid accumulation and is a common histological and radiological finding. Non-alcoholic fatty liver disease (NAFLD), or metabolic dysfunction associated steatotic liver disease (MASLD), is highly associated with metabolic syndrome and represents the most common cause of hepatic steatosis. However, since several comorbidities, lifestyle factors, and drugs can cause hepatic steatosis, MASLD is, to some extent, a diagnosis of exclusion. Nevertheless, initiatives have been taken to encompass positive (instead of negative) criteria for diagnosis - such as the presence of cardiometabolic risk factors together with hepatic steatosis. Nonetheless, before confirming a patient with MASLD, it is essential to map and evaluate other causes of fatty liver disease or steatotic liver disease. Several causes of hepatic steatosis have been identified in studies; however, the study cohorts are scarce and often anecdotal. Additionally, many studies have shown correlation without proving causation, and many are retrospective without reporting relevant patient characteristics and comorbidities - making it difficult to draw conclusions regarding the underlying etiology or present comorbidity of hepatic steatosis. In this narrative review, we aimed to identify and summarize present studies evaluating the impact of the most common and often suggested causes of hepatic steatosis.

Keywords

Hepatic steatosis / SLD / alcohol-related liver disease / alcohol-associated liver disease / ALD / methotrexate / tamoxifen / non-alcoholic fatty liver disease / NAFLD / metabolic-dysfunction associated liver disease / MASLD / MetALD / fatty liver disease

References

[1] Browning JD,Dobbins R.Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.Hepatology2004;40:1387-95

[2] Younossi ZM,Afendy M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol2011;9:524-530.e1; quiz e60

[3] Loomba R.The global NAFLD epidemic.Nat Rev Gastroenterol Hepatol2013;10:686-90

[4] Rinella ME,Ratziu V. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext [Last accessed on 23 Oct 2023]

[5] Rinella ME,Ratziu V. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Available from: https://www.sciencedirect.com/science/article/pii/S1665268123002375 [Last accessed on 23 Oct 2023]

[6] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[7] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2023:S0168-8278(23)05080

[8] Rinella ME,Ratziu V. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Available from:https://journals.lww.com/hep/fulltext/9900/a_multi_society_delphi_consensus_statement_on_new.488.aspx [Last accessed on 23 Oct 2023]

[9] Sherlock S. The Clinician Looks at Fatty Liver.

[10] Brunt EM,Wilson LA,Neuschwander-Tetri BA.NASH Clinical Research Network (CRN)Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.Hepatology2011;53:810-20 PMCID:PMC3079483

[11] Kleiner DE,Van Natta M.Nonalcoholic Steatohepatitis Clinical Research NetworkDesign and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology2005;41:1313-21

[12] Nasr P,Ignatova S.Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis.Gastro2017;153:53-55.e7

[13] Szczepaniak LS,Leonard D.Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.Am J Physiol Endocrinol Metab2005;288:E462-8

[14] Karlas T,Sasso M.Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.J Hepatol2017;66:1022-30

[15] Saad L. Majority in US drink alcohol, averaging four drinks a week. Available from: https://news.gallup.com/poll/156770/majority-drink-alcohol-averaging-four-drinks-week.aspx [Last accessed on 22 Oct 2023]

[16] Trolldal B. Alkoholkonsumtionen i Sverige 2017. CAN Rapport 175. Hämtad från Centralförbundet för alkohol-och narkotikaupplysnings webbplats: Available from: https://www.can.se/app/uploads/2020/01/can-rapport-175-alkoholkonsumtionen-i-sverige-2017.pdf [Last accessed on 22 Oct 2023]

[17] Eurobarometer S. EU citizens’ attitudes towards alcohol. Available from: https://data.europa.eu/data/datasets/s798_72_3_ebs331?locale=en[Last accessed on 23 Oct 2023]

[18] Zhou Z,Song Z,McClain CJ.A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production.Am J Pathol2003;163:1137-46 PMCID:PMC1868249

[19] Chen J,Li J.Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.Alcohol Clin Exp Res2021;45:2103-17 PMCID:PMC8602761

[20] Belfrage P,Cronholm T.Prolonged administration of ethanol to young, healthy volunteers: effects on biochemical, morphological and neurophysiological parameters.Acta Med Scand Suppl1973:552:1-44.

[21] Kechagias S,Gjellan S.Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study.Ann Med2011;43:545-54

[22] Rasmussen DN,Johansen S.GALAXYMicrobLiver consortiaPrognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.J Hepatol2021;75:1017-25 PMCID:PMC8522804

[23] Thiele M,Fluhr G.Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.J Hepatol2018;68:1025-32

[24] Donohue TM Jr.Alcohol-induced steatosis in liver cells.World J Gastroenterol2007;13:4974-8 PMCID:PMC4434621

[25] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8.

[26] Diehl AM,Ishak KG.Alcohollike liver disease in nonalcoholics. a clinical and histologic comparison with alcohol-induced liver injury.Gastro1988;95:1056-62.

[27] Lee RG.Nonalcoholic steatohepatitis: a study of 49 patients.Hum Pathol1989;20:594-8.

[28] Dam-Larsen S,Andersen IB.Long term prognosis of fatty liver: risk of chronic liver disease and death.Gut2004;53:750-5 PMCID:PMC1774026

[29] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.Obes Facts2016;9:65-90 PMCID:PMC5644799

[30] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease.J Hepatol2018;69:154-81

[31] Selin KH.Test-retest reliability of the alcohol use disorder identification test in a general population sample.Alcohol Clin Exp Res2003;27:1428-35

[32] Saunders JB,Babor TF,Grant M.Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II.Addiction1993;88:791-804.

[33] Bush K,McDonell MB,Bradley KA.The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). alcohol use disorders identification test.Arch Intern Med1998;158:1789-95

[34] Seitz HK.Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase.Am J Clin Nutr2006;83:1252-3

[35] Gough G,Puckett D.The utility of commonly used laboratory tests to screen for excessive alcohol use in clinical practice.Alcohol Clin Exp Res2015;39:1493-500 PMCID:PMC4515204

[36] Hock B,Domke I.Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.Addiction2005;100:1477-86

[37] Reynaud M,Loisequx-Meunier MN,Maradeix B,Gillet C.Objective diagnosis of alcohol abuse: compared values of carbohydrate-deficient transferrin (CDT), gamma-glutamyl transferase (GGT), and mean corpuscular volume (MCV).Alcohol Clin Exp Res2000;24:1414-9.

[38] Staufer K,Vettorazzi E,Nashan B.Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption.Hepatology2011;54:1640-9

[39] Helander A,Anton R.International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Standardisation of Carbohydrate-Deficient Transferrin (IFCC WG-CDT)Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT).Clin Chim Acta2016;459:19-24

[40] Niemelä O.Biomarker-based approaches for assessing alcohol use disorders.Int J Environ Res Public Health2016;13:166 PMCID:PMC4772186

[41] Anton RF,Tabakoff B.Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study.Alcoholism Clin Exp Res2002;26:1215-22

[42] Anton RF.Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. what have we learned?.Alcohol2001;25:185-8

[43] Hartmann S,Graf M.Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin.Addict Biol2007;12:81-4

[44] Schröck A,Schürch S.Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers.Int J Legal Med2017;131:153-60

[45] Kechagias S,Blomgren A.Phosphatidylethanol compared with other blood tests as a biomarker of moderate alcohol consumption in healthy volunteers: a prospective randomized study.Alcohol Alcohol2015;50:399-406

[46] Walther L,Löf E.Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level.Alcohol Clin Exp Res2015;39:2200-8

[47] Long MT,Hoffmann U,Naimi TS.Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease.Clin Gastroenterol H2020;18:1831-1841.e5 PMCID:PMC7569606

[48] Bellentani S,Masutti F.Prevalence of and risk factors for hepatic steatosis in Northern Italy.Ann Intern Med2000;132:112-7

[49] Lau K,Lieb W.The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women.Aliment Pharmacol Ther2015;41:467-76

[50] Staufer K,Strebinger G.Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.J Hepatol2022;77:918-30

[51] Dunn W,Brunt EM.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).J Hepatol2012;57:384-91 PMCID:PMC3399018

[52] Kwon HK,Conjeevaram HS.Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease.Liver Int2014;34:129-35

[53] Cao G,Liu Q,Tang S.Alcohol consumption and risk of fatty liver disease: a meta-analysis.PeerJ2016;4:e2633 PMCID:PMC5088606

[54] Moriya A,Ohguchi S.Roles of alcohol consumption in fatty liver: a longitudinal study.J Hepatol2015;62:921-7

[55] Hagström H,Ekstedt M.Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.Scand J Gastroenterol2017;52:159-65

[56] Hajifathalian K,McCullough AJ.Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study.Hepatology2019;70:511-21 PMCID:PMC6380949

[57] Ekstedt M,Holmqvist M.Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.Scand J Gastroenterol2009;44:366-74

[58] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology2010;51:1972-8

[59] Ajmera V,Wilson LA.Nonalcoholic Steatohepatitis Clinical Research NetworkAmong patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis.Clin Gastroenterol Hepatol2018;16:1511-1520.e5 PMCID:PMC6098737

[60] Kimura T,Fujimori N.Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.World J Gastroenterol2018;24:1440-50 PMCID:PMC5889824

[61] Ronksley PE,Turner BJ,Ghali WA.Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis.BMJ2011;342:d671 PMCID:PMC3043109

[62] 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016.Lancet2018;392:1015-35 PMCID:PMC6148333

[63] Åberg F,Puukka P,Jula A.Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population.Hepatology2018;67:2141-9

[64] Chang Y,Kim Y.Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study.Hepatology2019;69:64-75

[65] Younossi ZM,Ong J.Global NASH CouncilEffects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease.Clin Gastroenterol Hepatol2019;17:1625-1633.e1

[66] Hagström H.Considerations in the search for under-reported alcohol consumption in NAFLD.J Hepatol2023;78:e66-7

[67] Ezhilarasan D.Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms.Toxicology2021;458:152840

[68] Malaviya AN,Agarwal D,Garg S.Low-dose and high-dose methotrexate are two different drugs in practical terms.Int J Rheum Dis2010;13:288-93

[69] Roenigk HH,Curtis GH.Methotrexate for psoriasis in weekly oral doses.Arch Dermatol1969;99:86-93.

[70] Sundbaum J, Eriksson N, Hallberg P, Lehto N, Wadelius M, Baecklund E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: a long-term follow-up of predictors, surveillance, and outcome in clinical practice.Int J Rheum Dis2019;22:1226-32 PMCID:PMC6767545

[71] Schröder T,Olsen V.Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.Eur J Gastroenterol Hepatol2015;27:698-704

[72] Mori S,Ito M,Kamo Y.Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.PLoS One2018;13:e0203084 PMCID:PMC6108522

[73] Chalmers RJ,Kirby B.Liver biopsies and methotrexate: a time for reconsideration?.J Am Acad Dermatol2001;44:879-80

[74] Zachariae H,Søgaard H.Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment.Br J Dermatol1980;102:407-12.

[75] Zachariae H,Heickendorff L.Methotrexate-induced liver cirrhosis. clinical, histological and serological studies--a further 10-year follow-up.Dermatology1996;192:343-6

[76] Zachariae H.Liver biopsy in methotrexate treatment.Acta Derm Venereol1971;51:215-20.

[77] Gelfand JM,Zhang H.Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study.J Am Acad Dermatol2021;84:1636-43

[78] Ruan Z,Chen Y.Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults.JAMA Dermatol2022;158:745-53 PMCID:PMC9134040

[79] Maybury CM,Kloczko E.Prevalence of advanced liver fibrosis in patients with severe psoriasis.JAMA Dermatol2019;155:1028-32 PMCID:PMC6552112

[80] Laharie D,Schaeverbeke T.Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.J Hepatol2010;53:1035-40

[81] Choi Y,Kim IH,Park S.Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study.Clin Rheumatol2021;40:2037-45

[82] Tomaszewski M,Mohajerani SA.Hepatic steatosis as measured by the computed attenuation parameter predicts fibrosis in long-term methotrexate use.Can Liver J2021;4:370-80 PMCID:PMC9235122

[83] Erre GL,Sauchella A.Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study.Ther Adv Musculoskelet Dis2021;13:1759720X211042739 PMCID:PMC8606981

[84] Association for the Study of the Liver. Electronic address: [e-mail], Clinical Practice Guideline Panel: Chair:, Panel members, EASL Governing Board representative:. EASL clinical practice guidelines: drug-induced liver injury.J Hepatol2019;70:1222-61

[85] Lee B,Yoo JJ.Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: a systematic review and meta-analysis.Liver Int2020;40:1344-55

[86] Lelliott CJ,Curtis RK.Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis.FASEB J2005;19:1108-19

[87] Gudbrandsen OA,Berge RK.Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver.J Lipid Res2006;47:2223-32

[88] Cole LK,Vance DE.Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis.Hepatology2010;52:1258-65

[89] Bruno S,Castellana P.Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.BMJ2005;330:932 PMCID:PMC556336

[90] Elefsiniotis IS,Ilias A.Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.Eur J Gastroen Hepat2004;16:593-8

[91] Osman KA,Ahmed MH.Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?.Expert Opin Drug Saf2007;6:1-4

[92] Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom.QJM2000;93:105-11

[93] Overman RA,Deal CL.Prevalence of oral glucocorticoid usage in the United States: a general population perspective.Arthritis Care Res2013;65:294-8.

[94] Tarantino G.Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.World J Gastroenterol2013;19:6735-43 PMCID:PMC3812473

[95] Rahimi L,Ismail-Beigi F.Glucocorticoid-induced fatty liver disease.Diabetes Metab Syndr Obes2020;13:1133-45 PMCID:PMC7171875

[96] Buzzetti E,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).Metabolism2016;65:1038-48

[97] Li JX.Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions.Nat Rev Endocrinol2022;18:540-57 PMCID:PMC9116713

[98] Rockall AG,Evans D.Hepatic steatosis in cushing's syndrome: a radiological assessment using computed tomography.Eur J Endocrinol2003;149:543-8.

[99] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[100] Hubel JM,Mason RA.EMIL-Study GroupInfluence of plasma cortisol and other laboratory parameters on nonalcoholic Fatty liver disease.Horm Metab Res2015;47:479-84

[101] Pagano G,Cassader M.An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects.J Clin Invest1983;72:1814-20 PMCID:PMC370470

[102] Gulliford MC,Latinovic R.Risk of diabetes associated with prescribed glucocorticoids in a large population.Diabetes Care2006;29:2728-9.

[103] Negro F.Abnormalities of lipid metabolism in hepatitis C virus infection.Gut2010;59:1279-87

[104] Mihm S,Hartmann H.Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype.Hepatology1997;25:735-9

[105] Patton HM,Behling C.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.J Hepatol2004;40:484-90

[106] Rubbia-Brandt L,Abid K.Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.J Hepatol2000;33:106-15

[107] Adinolfi LE,Andreana A,Utili R.Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.Hepatology2001;33:1358-64

[108] Kumar D,Fung C.Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response.Hepatology2002;36:1266-72

[109] Lonardo A,Adinolfi LE,Ruggiero G.Hepatitis C and steatosis: a reappraisal.J Viral Hepat2006;13:73-80

[110] Hofer H,Wrba F.Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.Am J Gastroenterol2002;97:2880-5

[111] Serfaty L,Giral P,Chazouillères O.Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.J Hepatol2001;34:428-34

[112] Leslie J,Elsharkawy AM,Vacca M.Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.J Hepatol2022;77:219-36.

[113] Felmlee DJ,Lefevre M,Schuster C.Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.Viruses2013;5:1292-324 PMCID:PMC3712309

[114] Monto A,Watson JJ,Wright TL.Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.Hepatology2002;36:729-36

[115] Rubbia-Brandt L,Paganin S.Steatosis affects chronic hepatitis C progression in a genotype specific way.Gut2004;53:406-12 PMCID:PMC1773989

[116] Kim MN,Yoo J,Ahn SH.Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver.Aliment Pharmacol Ther2022;55:97-107

[117] Shimizu K,Sato M.Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.Sci Rep2018;8:7845 PMCID:PMC5959884

[118] Shousha HI,Azab SM.Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.J Med Virol2018;90:1099-105

[119] Rout G,Patel AH.Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography.J Clin Exp Hepatol2019;9:207-14 PMCID:PMC6477071

[120] Do A,Krishnan S.Excess weight gain after cure of hepatitis C infection with direct-acting antivirals.J Gen Intern Med2020;35:2025-34. PMCID:PMC7352003

[121] Kalligeros M,Shehadeh F.Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2023;21:1708-22

[122] Maurice JB,Scott AJ,Thursz M.Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.AIDS2017;31:1621-32.

[123] Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of non-alcoholic fatty liver disease in HIV-infected patients: the next big thing?.Infect Dis Ther2019;8:33-50 PMCID:PMC6374241

[124] Gutierrez AD.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Endocrine2012;41:1-10. PMCID:PMC3417129

[125] Magkos F.Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Metabolism2011;60:749-53. PMCID:PMC3036773

[126] Wiersinga WJ,Cheng AC,Prescott HC.Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review.JAMA2020;324:782-93

[127] Zhang C,Wang FS.Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol2020;5:428-30 PMCID:PMC7129165

[128] Kulkarni AV,Tevethia HV.Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.Aliment Pharmacol Ther2020;52:584-99 PMCID:PMC7361465

[129] Nardo AD,Bakail M,Lax SF.Pathophysiological mechanisms of liver injury in COVID-19.Liver Int2021;41:20-32. PMCID:PMC7753756

[130] Wang Y,Liu H.SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.J Hepatol2020;73:807-16. PMCID:PMC7211738

[131] Yang C,Xiao SY.Pathologic characteristics of digestive tract and liver in patients with coronavirus disease 2019.Gastroenterol Clin North Am2023;52:201-14. PMCID:PMC9531645

[132] Roca-Fernández A,Nicholls R.Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19.Front Med2021;8:636637 PMCID:PMC8039134

[133] Palomar-Lever A,Galicia-Alba J.Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: a computed tomography study.JGH Open2020;4:1102-7 PMCID:PMC7436487

[134] Bradley BT,Johnston R.Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series.Lancet2020;396:320-32. PMCID:PMC7365650

[135] Fassan M,Sbaraglia M.Liver histopathology in COVID-19 patients: a mono-Institutional series of liver biopsies and autopsy specimens.Pathol Res Pract2021;221:153451 PMCID:PMC8054534

[136] Beigmohammadi MT,Safaei M.Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients.Int J Surg Pathol2021;29:135-45 PMCID:PMC8041443

[137] Duarte-Neto AN,da Silva LFF.Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy.Histopathology2020;77:186-97 PMCID:PMC7280721

[138] Elsoukkary SS,Dillard A.Autopsy findings in 32 patients with COVID-19: a single-institution experience.Pathobiology2021;88:56-68. PMCID:PMC7573917

[139] Falasca L,Colombo D.Postmortem findings in italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities.J Infect Dis2020;222:1807-15 PMCID:PMC7543426

[140] Rapkiewicz AV,Carsons SE.Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series.EClinicalMedicine2020;24:100434 PMCID:PMC7316051

[141] Lagana SM,Iuga AC.Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data.Modern Pathology2020;33:2147-55 PMCID:PMC7424245

[142] Sonzogni A,Seghezzi M.Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations.Liver Int2020;40:2110-6. PMCID:PMC7404964

[143] Tian S,Liu H.Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.Mod Pathol2020;33:1007-14. PMCID:PMC7156231

[144] Trevenzoli M,Alberici I.SARS-CoV-2 and hepatitis.J Gastrointestin Liver Dis2020;29:473-5

[145] Zhao CL,Maghsoodi-Deerwester M.Pathological findings in the postmortem liver of patients with coronavirus disease 2019 (COVID-19).Hum Pathol2021;109:59-68 PMCID:PMC7722493

[146] Greuel S,Dragomir MP.COVID-19: autopsy findings in six patients between 26 and 46 years of age.Int J Infect Dis2021;108:274-81 PMCID:PMC8172269

[147] Xu Z,Wang Y.Pathological findings of COVID-19 associated with acute respiratory distress syndrome.Lancet Respir Med2020;8:420-2 PMCID:PMC7164771

[148] Cai Q,Yu H.COVID-19: abnormal liver function tests.J Hepatol2020;73:566-74 PMCID:PMC7194951

[149] McConnell MJ,Kondo R.Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.J Hepatol2021;75:647-58 PMCID:PMC8285256

[150] Yurdaisik I,Oz AB.Postmortem biopsies of the lung, heart, liver, and spleen of COVID-19 patients.Cureus2021;13:e20734 PMCID:PMC8792123

[151] Ramos-Rincon JM,García-Sevila R.Histopathological and virological features of lung, heart and liver percutaneous tissue core biopsy in patients with COVID-19: a clinicopathological case series.Malays J Pathol2022;44:83-92.

[152] Chornenkyy Y,Brucal M.Liver pathology and SARS-CoV-2 detection in formalin-fixed tissue of patients with COVID-19.Am J Clin Pathol2021;155:802-14 PMCID:PMC8135761

[153] Fraga M,Artru F.Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis.J Hepatol2020;73:967-70. PMCID:PMC7308036

[154] Williamson EJ,Bhaskaran K.Factors associated with COVID-19-related death using openSAFELY.Nature2020;584:430-6 PMCID:PMC7611074

[155] Wahlang B,Beier JI.Mechanisms of environmental contributions to fatty liver disease.Curr Environ Health Rep2019;6:80-94 PMCID:PMC6698418

[156] Wahlang B,Clair HB.Toxicant-associated steatohepatitis.Toxicol Pathol2013;41:343-60 PMCID:PMC5114851

[157] Foulds CE,York B.Endocrine-disrupting chemicals and fatty liver disease.Nat Rev Endocrinol2017;13:445-57 PMCID:PMC5657429

[158] Shi H,Hardesty JE.Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic function: Implications for nonalcoholic steatohepatitis and diabetes.Toxicol Appl Pharmacol2019;363:22-33 PMCID:PMC7059560

[159] Lonardo A,Lugari S.NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management.Int J Mol Sci2019;20:2841 PMCID:PMC6600657

[160] Cotter TG.Nonalcoholic fatty liver disease 2020: the state of the disease.Gastroenterology2020;158:1851-64

[161] Ferrandino G,Spadaro O.Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms.Proc Natl Acad Sci U S A2017;114:E9172-80 PMCID:PMC5664516

[162] Adams LA,Lindor KD.Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.Hepatology2004;39:909-14.

[163] Liangpunsakul S.Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?.J Clin Gastroenterol2003;37:340-3

[164] Chung GE,Kim W.Non-alcoholic fatty liver disease across the spectrum of hypothyroidism.J Hepatol2012;57:150-6

[165] Xu L,Miao M.Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study.J Hepatol2012;57:1153-4

[166] Lonardo A,Mantovani A,Lugari S.Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity?.Dig Liver Dis2019;51:462-70

[167] Harrison SA,Guy CD.Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet2019;394:2012-24

[168] Cerda C,Riquelme A.Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.J Hepatol2007;47:412-7.

[169] Rocha ALL,Guimarães TCM.Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.J Endocrinol Invest2017;40:1279-88

[170] Jones H,Pugh CJ.Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.J Clin Endocrinol Metab2012;97:3709-16

[171] Kim S,Park JH.A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease.BMC Gastroenterol2012;12:69 PMCID:PMC3406998

[172] Nikolaenko L,Wang C.Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.Endocrinology2014;155:417-28. PMCID:PMC5393315

[173] Senmaru T,Okada H.Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet.Metabolism2013;62:851-60

[174] Pericleous M,Wang T,Ala A.Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency.Lancet Gastroenterol2017;2:670-9

[175] Polyzos SA,Mantzoros CS.Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.Metabolism2019;96:66-82

[176] Di Filippo M,Roy P.Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia.J Hepatol2014;61:891-902

[177] Bernstein DL,Bialer MG.Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease.J Hepatol2013;58:1230-43

[178] Burton BK,Feillet F.A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency.N Engl J Med2015;373:1010-20.